As of June 17, 2025, Cardax Inc (CDXI) reports a ROE (Return on Equity) of 49.57%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Cardax Inc's ROE (Return on Equity)
Over recent years, Cardax Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2020-12-31 | 49.57% |
| 2019-12-31 | 70.75% |
| 2018-12-31 | 113.83% |
| 2017-12-31 | 141.25% |
| 2016-12-31 | 45.91% |
This gradual decrease highlights how Cardax Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Cardax Inc's ROE (Return on Equity) to Peers
To better understand Cardax Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Cardax Inc (CDXI) | 49.57% |
| Medican Enterprises Inc (MDCN) | 680.75% |
| Spotlight Innovation Inc (STLT) | 396.49% |
| Quanta Inc (QNTA) | 386.33% |
| Cannabis Global, Inc. (CBGL) | 354.30% |
| AtheroNova Inc (AHROQ) | 312.21% |
Compared to its competitors, Cardax Inc's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.